Jimmy Lin: A simple new blood test that can catch cancer early
TED Fellow Jimmy Lin is developing technologies to catch cancer early. Full bio
Double-click the English transcript below to play the video.
friends or loved ones
in the audience
emotions of sadness and anger and fear,
from the front lines of cancer research.
the war on cancer.
developments within cancer research.
encoded by DNA
in the DNA called mutations
to go out of control.
I was part of the team at Johns Hopkins
the mutations of cancers.
over 90 projects in 70 countries
the genetic basis of these diseases.
of cancers are understood
is precision medicine,
to be able to treat cancers,
that are able to target cancers
of these tailor-made drugs,
their therapy for their patients,
to leverage the immune system
where we find the off switches of cancer,
to turn the immune system back on,
where you can take away immune cells
and put them back into the body
science fiction, doesn't it?
at the National Cancer Institute,
with some of the pioneers of this field
to explore all aspects in immunotherapy.
revolutions are ongoing,
with a skin cancer called melanoma.
has gone everywhere.
to map the mutations of this cancer
that targets one of the mutations.
the end of the story.
as one centimeter in diameter
in these different cancers
to different drugs.
that's highly effective,
that there's a small population
What do we do with this information?
advancements in cancer therapy earlier,
is early detection.
results in better outcomes,
if you detect cancer in stage four,
survive at five years.
this cancer as early as stage one,
of women are detected at stage one,
are detected in stages three and four.
better detection mechanisms for cancers.
fall into one of three categories.
for colon cancer.
like PSA for prostate cancer.
infrastructure to implement.
in some populations,
in some circumstances,
of false positives,
and unnecessary procedures.
while useful in some populations,
to all patients.
in women with dense breasts.
that is noninvasive,
to be able to detect cancers
giving a talk if it didn't.
this latest technology we've developed.
is a simple blood test.
while seemingly mundane,
and nutrients to your cells,
faster than normal cells,
of these cancer cells
genome sequencing projects,
to be large enough to cause symptoms,
to show up on imaging,
on medical procedures,
while they are relatively pretty small,
of DNA in the blood.
with a simple blood test --
is extract the DNA out of it.
will be from healthy cells.
less than one percent,
to be able to enrich this DNA
to be associated with cancer,
from the cancer genomics projects.
into DNA-sequencing machines
into A's, C's, T's and G's
of billions of letters
and computational methods
the small signal that's present,
of cancer DNA in the blood.
of really predicting right now
that we have today,
these recurrences of cancers
at University College London,
an example of one patient.
who undergoes surgery
and imaging methods.
the cancer comes back.
Are we able to catch this earlier?
we've been collecting blood serially
the amount of ctDNA in the blood.
of cancer DNA in the blood.
in subsequent time points
after subsequent points.
of cancer DNA in the blood,
for days 400 and 450.
in the cancer DNA in the blood.
over a hundred days earlier
where we can give therapies,
where we can do surgical interventions,
for the cancer to grow
for resistance to occur.
means the matter of life and death.
about this information.
we've done additional studies now
we can find these cancers.
of our standard physical exams,
we will be able to compare
signatures of cancer,
months to even years earlier.
of lives could be saved.
recent advancements in immunotherapy
are working feverishly
ABOUT THE SPEAKERJimmy Lin - Geneticist
TED Fellow Jimmy Lin is developing technologies to catch cancer early.
Why you should listen
C. Jimmy Lin, MD, PhD, MHS is the Chief Scientific Officer (CSO), Oncology at Natera and a TED Fellow. He comes from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Previously, at Johns Hopkins and Washington University in St. Louis, Lin was part of one of the first clinical genomics labs in academia and led the computational analyses of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma and melanoma.
Lin has published in top academic journals, such as Science, Nature and Cell, and he has been an expert in national and international media outlets, such as New York Times, Forbes, Bloomberg Businessweek, The Washington Post, and the Financial Times.
Jimmy Lin | Speaker | TED.com